Raphi Levy on Alpha Tau’s Mission to Expand Options for Cancer Patients скачать в хорошем качестве

Raphi Levy on Alpha Tau’s Mission to Expand Options for Cancer Patients

As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we’re showcasing the innovative companies presenting at the upcoming DealFlow Discovery Conference (January 28-29, at the Borgata in Atlantic City) and the executives behind them. In this episode of Mission Matters, I sit down with Raphi Levy, CFO of Alpha Tau, to talk about a groundbreaking approach to cancer treatment that’s designed to target tumors directly. Raphi explains how Alpha Tau’s Alpha DaRT technology works, why it’s shown powerful results across multiple tumor types, and how the treatment fits seamlessly into existing clinical workflows without requiring doctors to learn new procedures. We also dive into why the team is prioritizing cancers like pancreatic and brain tumors—areas where patients urgently need better options—and what major milestones are coming up as Alpha Tau advances through clinical trials. Raphi’s mission is simple but profound: help give cancer patients new choices, fewer side effects, and real hope where options are limited. This interview is part of our effort to help investors discover compelling companies ahead of the event — and to help CEOs introduce their story to the 1500+ conference attendees. Learn more about the event and presenting companies: https://dealflowdiscoveryconference.com/